Long‐Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis

Conclusion.A significant subset of patients with mPDAC can achieve long‐term survival (≥18 months) in 2018. We identified low NLR as a significant prognostic factor associated with long‐term survival in mPDAC.Implications for Practice.Metastatic pancreatic ductal adenocarcinoma (mPDAC) is one of the most lethal types of cancer. A subset of patients with mPDAC can achieve long‐term survival (≥18 months) with a modern chemotherapy regimen, such as FOLFIRINOX or gemcitabine/nab‐paclitaxel. We identified low neutrophil‐to‐lymphocyte ratio (NLR) as a significant prognostic factor associated with long‐term survival in mPDAC. Prognostic factors such as NLR might allow accurate selection of patients with mPDAC in order to consider individual therapeutic approaches. NLR should be used as a stratification factor in clinical trials.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Gastrointestinal Cancer Source Type: research

Related Links:

ConclusionHigh levels of lifestyle-related cancer-risk behaviors were found in most of the Hong Kong construction workers studied. The present study contributes to understanding how cancer-related lifestyle risk behaviors cluster among construction workers and relative impact factors of risk behaviors. It is essential to tailor health behavior interventions focused on multiple risk behaviors among different groups for further enlarging the effects on cancer prevention.
Source: Safety and Health at Work - Category: Occupational Health Source Type: research
We report one case, in which the patient presented to the emergency department with lower urinary tract symptoms, fever and consumptive syndrome. Acute prostatitis was initially suspected, but subsequently prostate adenocarcinoma was diagnosed.This case enables us to consider the possibility of prostate adenocarcinoma as the diagnose in patients with fever of unknown origin, and the role of procalcitonin to rule out the presence of infection.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 21 January 2020Source: European UrologyAuthor(s): Charalampos Fragkoulis, Georgios Papadopoulos, Konstantinos Ntoumas
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 21 January 2020Source: European UrologyAuthor(s): Jae Heon Kim, In Gab Jeong
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 21 January 2020Source: European UrologyAuthor(s): Chang Wook Jeong, Samuel L. Washington, Annika Herlemann, Scarlett L. Gomez, Peter R. Carroll, Matthew R. CooperbergAbstractBackgroundActive surveillance (AS)/watchful waiting (WW) strategy for localized prostate cancer (PCa) is increasingly and broadly endorsed as a preferred option for initial treatment of men with very low- and low-risk PCa, but outcomes can be difficult to analyze in traditional, population-based registries. The recently released Surveillance, Epidemiology, and End Results (SEER) Prostate with WW dataset provides an op...
Source: European Urology - Category: Urology & Nephrology Source Type: research
In a post-9/11 climate, Islamophobia has increased significantly in the UK and elsewhere in the West. ISIS-inspired terrorist attacks in the UK as well as in France, Belgium, Germany and, more recently, in Sri Lanka have triggered an increase in verbal and...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Social Etiologies and Disparities Source Type: news
ConclusionsElderly patients had the same management as young patients, with no difference in surgery or survival, but with an increase in early loss of autonomy.
Source: Journal of Visceral Surgery - Category: Surgery Source Type: research
CONCLUSION: A significant subset of patients with mPDAC can achieve long-term survival (≥18 months) in 2018. We identified low NLR as a significant prognostic factor associated with long-term survival in mPDAC. IMPLICATIONS FOR PRACTICE: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is one of the most lethal types of cancer. A subset of patients with mPDAC can achieve long-term survival (≥18 months) with a modern chemotherapy regimen, such as FOLFIRINOX or gemcitabine/nab-paclitaxel. We identified low neutrophil-to-lymphocyte ratio (NLR) as a significant prognostic factor associated with long-term survival...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Conclusions: This meta-analysis demonstrated that CD44 overexpression might be an unfavorable prognostic factor for CRC patients and could be used to predict poor differentiation, lymph node metastasis and distant metastasis. Introduction Although therapies for colorectal cancer (CRC) has improved in recent years, colorectal cancer is still the third most common cause of cancer related death worldwide (1). Metastasis are observed in 25% of patients at initial diagnosis and approximately 50% of patients will develop metastasis (2). Presently, the outcome prediction and the therapy schedule determination of CRC patie...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Endoscopy DOI: 10.1055/s-0043-109021For pancreatic solid lesions, ESGE recommends performing endoscopic ultrasound (EUS)-guided sampling as first-line procedure when a pathological diagnosis is required. Alternatively, percutaneous sampling may be considered in metastatic disease.Strong recommendation, moderate quality evidence.In the case of negative or inconclusive results and a high degree of suspicion of malignant disease, ESGE suggests re-evaluating the pathology slides, repeating EUS-guided sampling, or surgery.Weak recommendation, low quality evidence.In patients with chronic pancreatitis associated with a pancreati...
Source: Endoscopy - Category: Gastroenterology Authors: Tags: Guideline Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | France Health | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Pancreas | Pancreatic Cancer | Peritoneal Cancer | Study | Urology & Nephrology | Women